Symbol | Exchange | Currency |
|---|
Investing.com - TG (NASDAQ: TGTX) reported first quarter EPS of $-0.28, $0.08 better than the analyst estimate of $-0.36. Revenue for the quarter came in at $7.8M versus the...
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code for BRIUMVI (ublituximab-xiiy), for...
First quarter 2023 BRIUMVI net sales of $7.8 million Over 400 BRIUMVI prescriptions in the first partial quarter from 165+ healthcare providers at 125+ centers Payor coverage in...
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, May 1, 2023, at 8:30 ET to discuss...
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
| Average | 29.81 (+9.60% Upside) |
| High | 42.00 |
| Low | 6.00 |
| Price | 27.20 |
| No. of Analysts | 8 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Sell | Neutral | Buy |
| Technical Indicators | Buy | Strong Buy | Neutral | Strong Sell | Strong Buy |
| Summary | Buy | Buy | Neutral | Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 91.00 | 93.80 | 91.00 | -3.80 | -4.01% | 70.94K | London | |||
| 1.40 | 1.40 | 1.055 | 0.00 | 0.00% | 0.00 | London | |||
| 3.19 | 3.19 | 3.19 | 0.00 | 0.00% | 0.00 | London | |||
| 7.10 | 7.10 | 6.00 | 0.00 | 0.00% | 0.00 | London | |||
| 6.25 | 6.30 | 6.16 | +0.200 | +3.31% | 8.36M | London | |||
| 9.95 | 9.50 | 9.50 | -0.45 | -4.52% | 20.69K | London | |||
| 34.65 | 35.20 | 35.00 | +0.65 | +1.88% | 369.95K | London | |||
| 1.06 | 1.06 | 1.06 | 0.00 | 0.00% | 0.00 | London | |||
| 11.50 | 11.50 | 11.50 | 0.00 | 0.00% | 0.00 | London | |||
| 1,812.50 | 1,812.50 | 1,812.50 | 0.00 | 0.00% | 0.00 | London | |||
| 620.50 | 620.50 | 619.50 | 0.00 | 0.00% | 0.00 | London | |||
| 136.50 | 136.50 | 136.50 | 0.00 | 0.00% | 8.12K | London | |||
| 1.25 | 1.002 | 1.002 | 0.00 | 0.00% | 0.00 | London | |||
Invista REIM Holdingsderived | 14.625 | 9.00 | 14.625 | 0.00 | 0.00% | 0.00 | London | ||
| 75.60 | 78.80 | 72.60 | 0.00 | 0.00% | 0.00 | London |